Traders Purchase High Volume of Call Options on Bioventus (NASDAQ:BVS)

Bioventus Inc. (NASDAQ:BVS) saw unusually large options trading activity on Monday. Stock traders acquired 10,317 call options on the company. This is an increase of approximately 5,933% compared to the typical daily volume of 171 call options.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BVS. CJS Securities began coverage on shares of Bioventus in a report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price target on shares of Bioventus in a research note on Tuesday, June 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. Finally, Barrington Research restated an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a research note on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Bioventus presently has a consensus rating of “Buy” and an average target price of $14.20.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares during the period. Goldman Sachs Group Inc. increased its stake in Bioventus by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock valued at $1,486,000 after buying an additional 26,103 shares during the period. Legal & General Group Plc increased its stake in Bioventus by 100.9% in the 2nd quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock valued at $473,000 after buying an additional 35,873 shares during the period. Rhumbline Advisers raised its position in Bioventus by 20.6% during the 2nd quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock worth $431,000 after buying an additional 11,133 shares during the last quarter. Finally, Marshall Wace LLP raised its position in Bioventus by 32.5% during the 2nd quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock worth $1,401,000 after buying an additional 51,951 shares during the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Stock Performance

Shares of NASDAQ:BVS traded up $1.39 on Monday, reaching $11.87. The company’s stock had a trading volume of 501,946 shares, compared to its average volume of 467,663. Bioventus has a 52-week low of $5.81 and a 52-week high of $11.93. The stock has a market capitalization of $991.62 million, a P/E ratio of 28.95, a PEG ratio of 1.35 and a beta of 0.65. The stock’s 50-day moving average is $9.53 and its two-hundred day moving average is $8.84. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The firm had revenue of $132.09 million for the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, sell-side analysts forecast that Bioventus will post 0.77 EPS for the current year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.